

Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis

Comment on:

Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept

Sirs,

We read the article by Kumar *et al.*, which is the first to address the association between anti-carbamylated protein antibodies (anti-CarP) and the response to abatacept (ABA) in rheumatoid arthritis (RA), with great interest. The most striking findings were the better response (a significant reduction in δ -DAS28-PCR) to ABA in anti-CarP positive patients and a reduction in anti-CarP levels. No differences in the therapeutic response were found when analyzed according to ACPA nor rheumatoid factor status (1).

This prompted us to assess whether we could reproduce their observations. The PACTABA study is a Spanish multicenter, observational sub-study of the ASCORE trial (NCT02090556) (2), including active RA patients who had previously failed with ≥ 1 conventional DMARD or ≥ 1 biologic therapy. Subcutaneous ABA was administered (125 mg weekly) and patients were followed prospectively. The therapeutic response was determined by δ -DAS28 (baseline to 3 months) and EULAR response criteria at 3 months of follow-up. Seventy-nine patients were included, of whom only the 65 who had sufficient information for data extraction were analysed. Anti-CarP were assessed at 0 and 3 months by a homemade ELISA test using fetal calf serum (cut-off ≥ 132.5 AU; 96% specificity vs. healthy population). The study is supported by Bristol Myers Squibb (BMS).

Fifty-two patients were female (80%), with mean age of $55.1(\pm 13.9)$ years and a disease duration of $9.5(\pm 7.2)$ years. Eighty percent were ACPA positive and 58.5% had previously failed with ≥ 1 biologic therapy. At baseline, 28(43.1%) patients were anti-CarP positive and no difference in DAS28 was observed according to anti-CarP status. At three months of follow up, a significant reduction in δ -DAS28 was observed in anti-CarP positive patients compared with anti-CarP negative patients (-1.904 vs. -0.212 ; $p < 0.005$) (Fig. 1a). According to anti-CarP status, a similar proportion achieved a EULAR response (13/32(41%) vs. 8/21(38%); $p = \text{NS}$). However, EULAR responders had higher baseline anti-CarP levels than non-responders (451.3 ± 675.4 vs. 152.6 ± 158.3 ; $p = 0.018$) (Fig. 1b). In addition, responders showed a significant reduction in anti-CarP levels after 3 months on treat-




Fig. 1. a: δ -DAS28 according to anti-CarP status; **b:** anti-CarP levels according to EULAR response criteria; **c:** δ -DAS28 according to ACPA status; **d:** ACPA levels according to EULAR response criteria.

ment with ABA, a finding not observed in non-responders (-84.8 AU vs. $+34.92$ AU; $p:0.023$). No differences were observed in δ -DAS28 according to ACPA status (Fig. 1c) or ACPA baseline levels between responders and non-responders (Fig. 1d).

Our findings reaffirm the report by Kumar *et al.* and posit a debate on whether anti-CarP are an ABA response biomarker in RA patients. This could be due to the similar chemical structure in the antigenic targets (homocitrulline and citrulline) of anti-CarP and ACPA or to the wide overlap between the two antibodies in RA patients. Nonetheless, the environmental and genetic backgrounds of the two autoantibodies differ (3). Anti-CarP and ACPA are, independently, poor RA prognosis factors (4, 5) and inhibition studies have shown that the overlap is merely a casual finding (6).

ACPA have been shown to be a reliable ABA response biomarker in *post hoc* analyses from randomised controlled trials and large observational studies (7-9). However, neither we nor Kumar *et al.* (1) found differences in the treatment response according to ACPA status. This might be explained by the small sample size of the two studies.

The low sensitivity of anti-CarP (10), together with the overlap of anti-CarP with ACPA, casts doubt on the predictive value of anti-CarP in the treatment response to ABA. However, the findings of Kumar *et al.* and ourselves suggest that anti-CarP are an early response biomarker for ABA, which may be more specific but less sensitive than ACPA. Testing for anti-CarP could be especially useful in ACPA negative patients. These are exploratory analysis and the results should be interpreted with caution. Further studies should include larger populations and analyse long-term outcomes.

R. CASTELLANOS-MOREIRA¹, MD, PhD
 A. GOMEZ², PhD
 I. HARO³, MSc, PhD
 V. RUIZ-ESQUIDE¹, MD, PhD
 S. MARSAL², MD, PhD
 R. SANMARTI¹, MD, PhD

¹Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona;
²Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona;
³Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Consejo Superior de Investigaciones Científicas, Barcelona, Spain.

Letters to the Editors

Please address correspondence to:
Raimon Sanmarti,
Arthritis Unit - Rheumatology Department,
Hospital Clinic of Barcelona,
Villarroel 170,
08036 Barcelona, Spain.
E-mail: sanmarti@clinic.cat

Funding: this study was supported by
Bristol-Myers Squibb.

Competing interests: S. Marsal and R. Sanmarti
received grant support for this work; the other
authors have declared no competing interests.

© Copyright CLINICAL AND
EXPERIMENTAL RHEUMATOLOGY 2021.

References

1. KUMAR R, PIANTONI S, BOLDINI M *et al.*: Anticarbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. *Clin Exp Rheumatol* 2020 Apr 27 [Online ahead of print].
2. ALTEN R, MARIETTE X, BUCH M *et al.*: AB0361 ASCORE, a 2-year, observational, prospective multicentre study of subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice: 1-year interim analysis. *Ann Rheum Dis* 2019; 78; (Suppl. 2): 1639.
3. JIANG X, TROUW LA, VAN WESEMAEL *et al.*: Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. *Ann Rheum Dis* 2014; 73: 1761-8.
4. AJEGANOVA S, VAN STEENBERGEN HW, VERHEUL MK *et al.*: The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. *Ann Rheum Dis* 2017; 76: 112-8.
5. HUMPHREYS JH, VERHEUL MK, BARTON A *et al.*: Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2016; 75: 1139-44.
6. JUAREZ M, BANG H, HAMMAR F, REIMER U *et al.*: Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. *Ann Rheum Dis* 2016; 75: 1099-107.
7. ALTEN R, MARIETTE X, LORENZ HM *et al.*: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. *Clin Rheumatol* 2019; 38: 1413-24.
8. HARROLD LR, LITMAN HJ, CONNOLLY SE *et al.*: Comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are anti-CCP positive in the United States Corrona Registry. *Rheumatol Ther* 2019; 6: 217-30.
9. SOKOLOVE J, SCHIFF M, FLEISCHMANN R *et al.*: Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. *Ann Rheum Dis* 2016; 75: 709-14.
10. VERHEUL MK, BOHRINGER S, VAN DELFT MAM *et al.*: Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals. *Arthritis Rheumatol* 2018; 70: 1721-31.